Vaccination with a bacterial peptide conjugated to SARS-CoV-2 receptor-binding domain accelerates immunity and protects against COVID-19

Poor immunogenicity of critical epitopes can hamper vaccine efficacy. To boost immune recognition of non- or low-immunogenic antigens, we developed a vaccine platform based on the conjugation of a target protein to a chimeric designer peptide (CDP) of bacterial origin. Here, we exploited this immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Blanas, Athanasios, Karsjens, Haiko, de Ligt, Aafke, Huijbers, Elisabeth J.M., van Loon, Karlijn, Denisov, Stepan S., Durukan, Canan, Engbersen, Diederik J.M., Groen, Jan, Hennig, Sven, Hackeng, Tilman M., van Beijnum, Judy R., Griffioen, Arjan W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252865/
https://www.ncbi.nlm.nih.gov/pubmed/35813877
http://dx.doi.org/10.1016/j.isci.2022.104719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252865/
https://www.ncbi.nlm.nih.gov/pubmed/35813877
http://dx.doi.org/10.1016/j.isci.2022.104719

Ejemplares similares